Legend Biotech (LEGN) announces the appointment of Carlos Santos as the Company’s Chief Financial Officer, effective immediately. Santos assumes the role from Jessie Yeung, who has served as the interim CFO since January 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech’s Earnings Call: Growth and Success
- Legend Biotech price target raised to $77 from $75 at RBC Capital
- Positive Outlook for Legend Biotech: Strong Sales Growth and Strategic Advancements Drive Buy Rating
- Legend Biotech’s Strategic Growth and Record Sales Drive Buy Rating
- Strong Buy Rating for Legend Biotech Driven by CARVYKTI’s Market Success and Strategic Expansions